Brief: Anthera says blisibimod CHABLIS-SC1 phase 3 study did not achieve primary endpoint in patients with active systemic lupus erythematosus

Anthera Pharmaceuticals

10/11/2016 12:00

Nov 10 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O : 
    * Continuing to explore Blisibimod as treatment for IGA 
nephropathy - phase 2 data in December 
    * Sollpura solution phase 3 study in exocrine pancreatic 
insufficiency on track for topline data in December 
    * Anthera announces that the blisibimod CHABLIS-SC1 phase 3 
study did not achieve the primary endpoint in patients with 
active systemic lupus erythematosus 
 
Source text for Eikon:  ID:nGNXNKSIGa  
Further company coverage:  ANTH.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))